The most common patterns of resistance in EGFR-mutated NSCLC treated with osimertinib frontline are MET amplification, EGFR C797X-acquired mutation, and human epidermal growth factor 2 (HER2) amplification. Here, MET is linked to non-small cell lung carcinoma.